This disclosure relates to managing conditioned fear and conditions induced by experiencing or witnessing an extreme traumatic event using neurokinin receptor antagonists. In certain embodiments, the disclosure relates to methods of treating or preventing conditioned fear comprising administering an effective about neurokinin 3 receptor antagonist to a subject in need thereof. In certain embodiments, the subject is diagnosed with Post-Traumatic Stress Disorder. In certain embodiments, the neurokinin 3 receptor antagonist is (R)—N-{{3-[1-Benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]prop-1-yl}-4-phenylpiperidin-4-yl}-N-methylacetamine or salts thereof.

The present invention provides a method for safe and efficacious administration of esketamine.

The present invention provides a method for safe and efficacious administration of esketamine.

This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.

This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.

A method of treating or preventing a neuroinflammatory and/or neurodegenerative disease in a subject by administering a pharmaceutically effective amount of a CB.sub.2 receptor agonist is described. The CB.sub.2 receptor agonist can be a compound according to formula I

##STR00001##

or a pharmaceutically acceptable salt thereof, with R.sup.1 and R.sup.2 as defined herein. Administration of the CB.sub.2 receptor agonist activates CB.sub.2 receptors in the microglia, and can restore syntaptic plasticity, cognition, and memory in subjects having elevated levels of amyloid-β peptide in the brain.

A method of treating or preventing a neuroinflammatory and/or neurodegenerative disease in a subject by administering a pharmaceutically effective amount of a CB.sub.2 receptor agonist is described. The CB.sub.2 receptor agonist can be a compound according to formula I

##STR00001##

or a pharmaceutically acceptable salt thereof, with R.sup.1 and R.sup.2 as defined herein. Administration of the CB.sub.2 receptor agonist activates CB.sub.2 receptors in the microglia, and can restore syntaptic plasticity, cognition, and memory in subjects having elevated levels of amyloid-β peptide in the brain.

The present invention is directed to a method of treating or lessening the severity of cystic fibrosis in a patient, comprising the step of administering to said patient an effective amount of an inhibitor of S-nitrosoglutathione reductase (GSNOR) in combination with one or more secondary active agents.

The present invention is directed to a method of treating or lessening the severity of cystic fibrosis in a patient, comprising the step of administering to said patient an effective amount of an inhibitor of S-nitrosoglutathione reductase (GSNOR) in combination with one or more secondary active agents.

The present invention relates to a Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, for use in the treatment of impaired skin wound healing in a subject, an in vitro method for identifying a subject suffering from impaired skin wound healing to be responsive to the treatment with a Selective Glucocorticoid Receptor Modulator (SEGRM), or a pharmaceutically acceptable salt thereof, and kits and kits-of-part related thereto.